Referências
Principais artigos
Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.Texto completo Resumo
Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.Texto completo Resumo
Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.Texto completo Resumo
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].Texto completo
Artigos de referência
1. WHO Classification of Tumors Editorial Board. Female genital tumors. In: World Health Organization. Classification of tumors. 5th ed (vol. 4). World Health Organization, IARC Press; 5th ed (vol. 4). 2020.
2. World Health Organization. Cervical cancer. Mar 2024 [internet publication].Texto completo
3. European Commission: European Cancer Information System. Cervical cancer burden in EU-27. 2021 [internet publication].Texto completo
4. National Cancer Institute. Cancer stat facts: cervical cancer. 2025 [internet publication].Texto completo
5. Louie KS, de Sanjose S, Diaz M, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009 Apr 7;100(7):1191-7.Texto completo Resumo
6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1060-9.Texto completo Resumo
7. International Collaboration of Epidemiological Studies of Cervical Cancer; Appleby P, Beral V, Berrington de González A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006 Mar 15;118(6):1481-95.Texto completo Resumo
8. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018 Mar 27;32(6):795-808.Texto completo Resumo
9. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. Resumo
10. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7;370(9581):59-67. Resumo
11. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003 Jul 10;105(5):687-91.Texto completo Resumo
12. González CA, Travier N, Luján-Barroso L, et al. Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer. 2011 Jul 19;129(2):449-59.Texto completo Resumo
13. International Collaboration of Epidemiological Studies of Cervical Cancer., Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-21. Resumo
14. Landy R, Pesola F, Castañón A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016 Oct 25;115(9):1140-6.Texto completo Resumo
15. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340-48.Texto completo Resumo
16. Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021 Oct 1;113(10):1329-35.Texto completo Resumo
17. Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018 Aug;55(2):197-204.Texto completo Resumo
18. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Dec 4;398(10316):2084-92. Resumo
19. Liao CI, Francoeur AA, Kapp DS, et al. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open. 2022 Mar 1;5(3):e222530.Texto completo Resumo
20. Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022 Dec 15;379:e070115.Texto completo Resumo
21. Bonjour M, Charvat H, Franco EL, et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. 2021 Jul;6(7):e510-21.Texto completo Resumo
22. Sharma K, Machalek DA, Toh ZQ, et al. No woman left behind: achieving cervical cancer elimination among women living with HIV. Lancet HIV. 2023 Jun;10(6):e412-20. Resumo
23. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. November 2020 [internet publication].Texto completo
24. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. Resumo
25. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.Texto completo Resumo
26. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303-15. Resumo
27. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423-8.Texto completo Resumo
28. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999 Nov;180(5):1415-23.Texto completo Resumo
29. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Chapter 5: Human papillomavirus. Mar 2022 [internet publication].Texto completo
30. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1579-88.Texto completo Resumo
31. Watson RA. Human papillomavirus: confronting the epidemic – a urologist's perspective. Rev Urol. 2005 Summer;7(3):135-44.Texto completo Resumo
32. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985 Mar 7-13;314(6006):111-4. Resumo
33. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005 Dec;37(6):319-24.Texto completo Resumo
34. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002 Jan;3(1):11-6. Resumo
35. Kelly H, Weiss HA, Benavente Y, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018 Jan;5(1):e45-58.Texto completo Resumo
36. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. Resumo
37. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007 Feb 15;120(4):885-91. Resumo
38. Exposure in utero to diethylstilbestrol and related synthetic hormones. Association with vaginal and cervical cancers and other abnormalities. JAMA. 1976 Sep 6;236(10):1107-9. Resumo
39. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 22;284(15):878-81.Texto completo Resumo
40. Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 2011 Oct 6;365(14):1304-14.Texto completo Resumo
41. Verloop J, van Leeuwen FE, Helmerhorst TJ, et al. Cancer risk in DES daughters. Cancer Causes Control. 2010 Jul;21(7):999-1007.Texto completo Resumo
42. Huo D, Anderson D, Palmer JR, et al. Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. Gynecol Oncol. 2017 Sep;146(3):566-71. Resumo
43. White MC, Weir HK, Soman AV, et al. Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero. Cancer Causes Control. 2022 Aug;33(8):1121-4. Resumo
44. Marcus JZ, Nelson E, Linder M, et al. ASCCP clinical consensus: screening recommendations for clear cell adenocarcinomas in people exposed to DES in utero. J Low Genit Tract Dis. 2024 Oct 1;28(4):351-5.Texto completo Resumo
45. Bowden SJ, Doulgeraki T, Bouras E, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023 Jul 27;21(1):274. Resumo
46. Hamar B, Teutsch B, Hoffmann E, et al. Trichomonas vaginalis infection is associated with increased risk of cervical carcinogenesis: a systematic review and meta-analysis of 470 000 patients. Int J Gynaecol Obstet. 2023 Oct;163(1):31-43.Texto completo Resumo
47. Bhuvanendran Pillai A, Mun Wong C, Dalila Inche Zainal Abidin N, et al. Chlamydia infection as a risk factor for cervical cancer: a systematic review and meta-analysis. Iran J Public Health. 2022 Mar;51(3):508-17.Texto completo Resumo
48. Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' oral contraception study. Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-9.Texto completo Resumo
49. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006 Sep 1;119(5):1108-24.Texto completo Resumo
50. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002 Apr 11;346(15):1105-12.Texto completo Resumo
51. Svare EI, Kjaer SK, Worm AM, et al. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002 Jun;78(3):215-8.Texto completo Resumo
52. Kim J, Kim BK, Lee CH, et al. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer. 2012 Nov;22(9):1570-6. Resumo
53. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control. 1996 Jan;7(1):113-26. Resumo
54. Xu L, Tan Y, Xiang P, et al. Diet-related risk factors for cervical cancer: data from National Health and Nutrition Examination Survey 1999-2018. Nutr Cancer. 2023;75(10):1892-9. Resumo
55. Yeo AS, Schiff MA, Montoya G, et al. Serum micronutrients and cervical dysplasia in Southwestern American Indian women. Nutr Cancer. 2000;38(2):141-50. Resumo
56. Cao D, Shen K, Li Z, et al. Association between vitamin C Intake and the risk of cervical neoplasia: a meta-analysis. Nutr Cancer. 2016;68(1):48-57. Resumo
57. Hu X, Li S, Zhou L, et al. Effect of vitamin E supplementation on uterine cervical neoplasm: a meta-analysis of case-control studies. PLoS One. 2017 Aug 22;12(8):e0183395.Texto completo Resumo
58. Sikström B, Hellberg D, Nilsson S, et al. Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Arch Gynecol Obstet. 1995;256(3):131-7. Resumo
59. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23.Texto completo Resumo
60. Centers for Disease Control and Prevention. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Nov 2016 [internet publication].Texto completo
61. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. Resumo
62. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. Resumo
63. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65. Resumo
64. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;(5):CD009069.Texto completo Resumo
65. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):575-90.Texto completo Resumo
66. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.Texto completo Resumo
67. Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008 Winter;1(1):2-10.Texto completo Resumo
68. Restrepo J, Herrera T, Samakoses R, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics. 2023 Oct 1;152(4):e2022060993.Texto completo Resumo
69. Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020 Oct 1;112(10):1038-46.Texto completo Resumo
70. Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021 Nov;22(11):1518-29.Texto completo Resumo
71. Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022 Jun;1(5):EVIDoa2100056.Texto completo Resumo
72. World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022 [internet publication].Texto completo
73. UK Health Security Agency. Human papillomavirus (HPV): the green book, chapter 18a. Jun 2023 [internet publication].Texto completo
74. UK Health Security Agency. HPV vaccination guidance for healthcare practitioners (version 6). Jun 2023 [internet publication].Texto completo
75. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020 Jul;70(4):274-80.Texto completo Resumo
76. Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age (addendum updated August 7, 2025): recommendations for ages 18 years or younger, United States, 2025. Oct 2025 [internet publication].Texto completo
77. National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Jul 2025 [internet publication].Texto completo
78. American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-21.Texto completo Resumo
79. Centers for Disease Control and Prevention. Adult immunization schedule by age (addendum updated August 7, 2025): recommendations for ages 19 years or older, United States, 2025. Oct 2025 [internet publication].Texto completo
80. Parazzini F, Negri E, La Vecchia C, et al. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 1989 Nov;40(5):519-30. Resumo
81. Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med. 2005 Feb 17;352(7):720-1. Resumo
82. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007 Nov 24;370(9601):1764-72. Resumo
83. Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017 Dec;130(6):1226-36. Resumo
84. Spotnitz ME, Natarajan K, Ryan PB, et al. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol. 2020 Feb;135(2):319-27.Texto completo Resumo
85. Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023 Aug;229(2):93-100. Resumo
86. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009 Oct 28;302(16):1757-64.Texto completo Resumo
87. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.Texto completo Resumo
88. American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. April 2021 [internet publication].Texto completo
89. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017 Aug 10;(8):CD008587.Texto completo Resumo
90. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018 Jul 3;320(1):43-52.Texto completo Resumo
91. Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Aug 21;320(7):687-705.Texto completo Resumo
92. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002 Apr 24;287(16):2114-9. Resumo
93. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol. 2015 May;123(5):271-81.Texto completo Resumo
94. Wang J, Andrae B, Sundström K, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ. 2016 Feb 11;352:i276.Texto completo Resumo
95. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989 Aug 18;262(7):931-4. Resumo
96. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-31.Texto completo Resumo
97. American College of Obstetricians and Gynecologists. Updated guidelines for management of cervical cancer screening abnormalities. October 2020 [internet publication].Texto completo
98. Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.Texto completo Resumo
99. Pain management for in-office uterine and cervical procedures: ACOG clinical consensus no. 9. Obstet Gynecol. 2025 May 15;146(1):161-77.Texto completo Resumo
100. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].Texto completo
101. Patel-Lippmann K, Robbins JB, Barroilhet L, et al. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am. 2017 Aug;25(3):635-49. Resumo
102. Fischerova D, Cibula D, Stenhova H, et al. Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):766-72. Resumo
103. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000 Aug;70(2):209-62. Resumo
104. Choi HJ, Ju W, Myung SK, et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010 Jun;101(6):1471-9.Texto completo Resumo
105. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004 Jul;94(1):212-6. Resumo
106. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007 Jul;106(1):29-34. Resumo
107. Gee MS, Atri M, Bandos AI, et al. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology. 2018 Apr;287(1):176-84.Texto completo Resumo
108. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011 Jun 25;119(3):158-66.Texto completo Resumo
109. US Food and Drug Administration. Recently approved devices: Ventana Medical Systems CINtec PLUS Cytology - P190024. 16 Apr 2020 [internet publication]. Texto completo
110. Dason ES, Maxim M, Sanders A, et al. Guideline no. 437: diagnosis and management of adenomyosis. J Obstet Gynaecol Can. 2023 Jun;45(6):417-29.e1. Resumo
111. Munro MG, Critchley HOD, Fraser IS, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018 Dec;143(3):393-408. Resumo
112. Royal College of Obstetricians and Gynaecologists. The initial management of chronic pelvic pain (green-top guideline no. 41). May 2012 [internet publication].Texto completo
113. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. May 2021 [internet publication].Texto completo
114. Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012 Jul;120(1):197-206. Resumo
115. Harmsen MJ, Van den Bosch T, de Leeuw RA, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. Ultrasound Obstet Gynecol. 2022 Jul;60(1):118-31.Texto completo Resumo
116. Van den Bosch T, Dueholm M, Leone FP, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015 Sep;46(3):284-98.Texto completo Resumo
117. Novellas S, Chassang M, Delotte J, et al. MRI characteristics of the uterine junctional zone: from normal to the diagnosis of adenomyosis. AJR Am J Roentgenol. 2011 May;196(5):1206-13.Texto completo Resumo
118. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019 Apr;145(1):129-35. Resumo
119. Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135]. 2019 Nov;147(2):279-80.Texto completo Resumo
120. Union for International Cancer Control Classification. UICC and the TNM classification of malignant tumours. June 2021 [internet publication].Texto completo
121. US Preventive Services Task Force. Cervical cancer: screening. Dec 2024 [internet publication].Texto completo
122. NHS England. Cervical screening: programme overview. Jul 2025 [internet publication].Texto completo
123. NHS England. Cervical screening: care pathway. Jul 2025 [internet publication].Texto completo
124. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. 2nd ed. Geneva: World Health Organization; 2021.Texto completo Resumo
125. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV). Dec 2021 [internet publication].Texto completo
126. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007 Jun 20;99(12):962-72. Resumo
127. Moscicki AB, Flowers L, Huchko MJ, et al. Updated review for guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2025 Apr 1;29(2):168-79.Texto completo Resumo
128. NHS England. 6. Screening and management of immunosuppressed individuals. Jul 2025 [internet publication].Texto completo
129. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016 Jul 28;354:i3633.Texto completo Resumo
130. Reynolds AC, McKenzie LJ. Cancer treatment-related ovarian dysfunction in women of childbearing potential: management and fertility preservation options. J Clin Oncol. 2023 Apr 20;4(12):2281-92.Texto completo Resumo
131. Su HI, Lacchetti C, Letourneau J, et al. Fertility preservation in people with cancer: ASCO guideline update. J Clin Oncol. 2025 Apr 20;43(12):1488-515.Texto completo Resumo
132. Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016 Jun;17(6):e240-53. Resumo
133. Alonso-Espías M, Gorostidi M, Gracia M, et al. Role of adjuvant radiotherapy in patients with cervical cancer undergoing radical hysterectomy. J Pers Med. 2023 Oct 12;13(10):1486.Texto completo Resumo
134. Rodriguez J, Viveros-Carreño D, Pareja R. Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update? Int J Gynecol Cancer. 2022 Oct 3;32(10):1219-26. Resumo
135. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008 Mar;9(3):297-303. Resumo
136. Querleu D, Cibula D, Abu-Rustum NR. 2017 Update on the Querleu-Morrow classification of radical hysterectomy. Ann Surg Oncol. 2017 Oct;24(11):3406-12.Texto completo Resumo
137. Schmeler KM, Pareja R, Lopez Blanco A, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021 Oct;31(10):1317-25.Texto completo Resumo
138. Kietpeerakool C, Aue-Aungkul A, Galaal K, et al. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). Cochrane Database Syst Rev. 2019 Feb 12;(2):CD012828.Texto completo Resumo
139. Plante M, Kwon JS, Ferguson S, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024 Feb 29;390(9):819-29.Texto completo Resumo
140. Kietpeerakool C, Rattanakanokchai S, Shawky M, et al. Simple hysterectomy with pelvic lymphadenectomy versus radical hysterectomy with pelvic lymphadenectomy for women with stage IA2-IB1 cervical cancer. Cochrane Database Syst Rev. 2025 Oct 15;10(10):CD012335. Resumo
141. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1895-904. Resumo
142. Uppal S, Gehrig PA, Peng K, et al. Recurrence rates in patients with cervical cancer treated with abdominal versus minimally invasive radical hysterectomy: a multi-institutional retrospective review study. J Clin Oncol. 2020 Apr 1;38(10):1030-40. Resumo
143. Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1905-14. Resumo
144. Falconer H, Palsdottir K, Stalberg K, et al. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019 Jul;29(6):1072-6. Resumo
145. ClinicalTrials.gov. A trial of robotic versus open hysterectomy surgery in cervix cancer (ROCC). April 2023 [internet publication].Texto completo
146. Committee on Gynecologic Practice. Committee opinion no. 619: gynecologic surgery in the obese woman. Obstet Gynecol. 2015 Jan;125(1):274-8.Texto completo Resumo
147. Bohn JA, Hernandez-Zepeda ML, Hersh AR, et al. Does obesity influence the preferred treatment approach for early-stage cervical cancer? A cost-effectiveness analysis. Int J Gynecol Cancer. 2022 Feb;32(2):133-40. Resumo
148. Salvo G, Ramirez PT, Leitao MM, et al. Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. Am J Obstet Gynecol. 2022 Jan;226(1):97.e1-97.e16.Texto completo Resumo
149. Gien LT, Covens A. Fertility-sparing options for early stage cervical cancer. Gynecol Oncol. 2010 May;117(2):350-7. Resumo
150. Slama J, Runnebaum IB, Scambia G, et al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: the FERTIlity Sparing Surgery retrospective multicenter study. Am J Obstet Gynecol. 2023 Apr;228(4):443.e1-443.e10. Resumo
151. Lintner B, Saso S, Tarnai L, et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. Int J Gynecol Cancer. 2013 Jul;23(6):1065-70. Resumo
152. Wethington SL, Sonoda Y, Park KJ, et al. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer. 2013 Jul;23(6):1092-8.Texto completo Resumo
153. Li J, Wu X, Li X, et al. Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors ≥ 2 cm? Gynecol Oncol. 2013 Oct;131(1):87-92. Resumo
154. Pareja R, Rendón GJ, Sanz-Lomana CM, et al. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol. 2013 Oct;131(1):77-82. Resumo
155. Bentivegna E, Maulard A, Pautier P, et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril. 2016 Oct;106(5):1195-211;e5.Texto completo Resumo
156. Kuznicki ML, Chambers LM, Morton M, et al. Fertility-sparing surgery for early-stage cervical cancer: a systematic review of the literature. J Minim Invasive Gynecol. 2021 Mar;28(3):513-26.e1. Resumo
157. Nezhat C, Roman RA, Rambhatla A, et al. Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review. Fertil Steril. 2020 Apr;113(4):685-703.Texto completo Resumo
158. Nezhat F, Erfani H, Nezhat C. A systematic review of the reproductive and oncologic outcomes of fertility-sparing surgery for early-stage cervical cancer. J Turk Ger Gynecol Assoc. 2022 Dec 8;23(4):287-313.Texto completo Resumo
159. Chino J, Annunziata CM, Beriwal S, et al. Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020 Jul-Aug;10(4):220-34.Texto completo Resumo
160. Landoni F, Colombo A, Milani R, et al. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017 May;28(3):e34.Texto completo Resumo
161. Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):667-76. Resumo
162. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: results of the national practice in cancer of the cervix. Cancer. 1983 Mar 1;51(5):959-67.Texto completo Resumo
163. Coia L, Won M, Lanciano R, et al. The patterns of care outcome study for cancer of the uterine cervix: results of the second national practice survey. Cancer. 1990 Dec 15;66(12):2451-6. Resumo
164. Montana GS, Martz KL, Hanks GE. Patterns and sites of failure in cervix cancer treated in the U.S.A. in 1978. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):87-93. Resumo
165. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021 Apr;22(4):538-47. Resumo
166. Sturdza AE, Knoth J. Image-guided brachytherapy in cervical cancer including fractionation. Int J Gynecol Cancer. 2022 Mar;32(3):273-80.Texto completo Resumo
167. Schmid MP, Lindegaard JC, Mahantshetty U, et al. Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. J Clin Oncol. 2023 Apr 1;41(10):1933-42. Resumo
168. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6. Resumo
169. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225.Texto completo Resumo
170. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10.Texto completo Resumo
171. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004 Mar 1;22(5):872-80.Texto completo Resumo
172. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85.Texto completo Resumo
173. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48. Resumo
174. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53.Texto completo Resumo
175. McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024 Oct 19;404(10462):1525-35.Texto completo Resumo
176. Andrade MO, Al-Alam OCM, Kim HJS, et al. Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2025 Jul;138:102959.Texto completo Resumo
177. Lindegaard JC, Petric P, Tan LT, et al. Are we making progress in curing advanced cervical cancer-again? Int J Gynecol Cancer. 2024 Dec 2;34(12):1940-5.Texto completo Resumo
178. Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer. 2008 May 1;112(9):1954-63.Texto completo Resumo
179. Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol. 2011 Aug;122(2):275-80.Texto completo Resumo
180. Lécuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol. 2011 May 1;29(13):1686-91.Texto completo Resumo
181. Cibula D, Kocian R, Plaikner A, et al. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. Eur J Cancer. 2020 Sep;137:69-80.Texto completo Resumo
182. Mauro J, Viveros-Carreño D, Vizzielli G, et al. Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review. Int J Gynecol Cancer. 2023 Sep 4;33(9):1370-5. Resumo
183. Tu H, Huang H, Li Y, et al. Sentinel-lymph-node biopsy alone or with lymphadenectomy in cervical cancer. N Engl J Med. 2025 Oct 16;393(15):1463-74. Resumo
184. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. Resumo
185. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43.Texto completo Resumo
186. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61.Texto completo Resumo
187. Kokka F, Bryant A, Olaitan A, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD010260.Texto completo Resumo
188. Lu W, Lu C, Yu Z, et al. Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: a systematic review and updated meta-analysis. Oncol Lett. 2021 Feb;21(2):160.Texto completo Resumo
189. Trifiletti DM, Swisher-McClure S, Showalter TN, et al. Postoperative chemoradiation therapy in high-risk cervical cancer: re-evaluating the findings of Gynecologic Oncology Group Study 109 in a large, population-based cohort. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1032-44. Resumo
190. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999 May;73(2):177-83. Resumo
191. Kim H, Park W, Kim YS, et al. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. J Gynecol Oncol. 2020 May;31(3):e35.Texto completo Resumo
192. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76. Resumo
193. Ryu SY, Deng W, Albuquerque K, et al. Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008. Ann Oncol. 2025 Sep 12:S0923-7534(25)04700-3.Texto completo Resumo
194. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Oct 5;404(10460):1321-32. Resumo
195. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073-126.Texto completo Resumo
196. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435.Texto completo Resumo
197. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immune checkpoint inhibitor-related toxicities. [internet publication].Texto completo
198. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55.Texto completo Resumo
199. Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35.Texto completo Resumo
200. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul;130(1):64-8.Texto completo Resumo
201. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-63.Texto completo Resumo
202. Rosen VM, Guerra I, McCormack M, et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer. 2017 Jul;27(6):1237-46.Texto completo Resumo
203. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33.Texto completo Resumo
204. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021 Nov 11;385(20):1856-67.Texto completo Resumo
205. Monk BJ, Tewari KS, Dubot C, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):392-402.Texto completo Resumo
206. Chuang LT, Temin S, Berek JS, et al. Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. JCO Glob Oncol. 2022 Mar;8:e2200027.Texto completo Resumo
207. Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial. JAMA Oncol. 2024 Feb 1;10(2):185-92.Texto completo Resumo
208. Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024 Jan 6;403(10421):31-43. Resumo
209. Giorgi UD, Mansi L, Martinez-Garcia J, et al. 10O Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial of first-line atezolizumab (atezo), chemotherapy (CT) and bevacizumab (bev) for metastatic, persistent or recurrent cervical cancer (R/M CC). ESMO Open. 2025;10:105140.Texto completo
210. Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019 Nov 1;37(31):2825-34.Texto completo Resumo
211. Oaknin A, Moore K, Meyer T, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial. Lancet Oncol. 2024 May;25(5):588-602. Resumo
212. Schenker M, Burotto M, Richardet M, et al. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. J Immunother Cancer. 2024 Aug 6;12(8):e008872.Texto completo Resumo
213. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020 Jan 1;38(1):1-10.Texto completo Resumo
214. Vergote I, González-Martín A, Fujiwara K, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024 Jul 4;391(1):44-55.Texto completo Resumo
215. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024 Jan 1;42(1):47-58.Texto completo Resumo
216. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006 Oct;7(10):837-47. Resumo
217. Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Int J Gynecol Cancer. 2023 May 1;33(5):649-66.Texto completo Resumo
218. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(suppl 6):vi160-70.Texto completo Resumo
219. Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019 Oct 1;30(10):1601-12.Texto completo Resumo
220. Zagouri F, Sergentanis TN, Chrysikos D, et al. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013 Feb;121(2 Pt 1):337-43. Resumo
221. Ryu SY, Deng W, Albuquerque K, et al. Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008. Ann Oncol. 2025 Sep 12.Texto completo Resumo
222. European Society for Medical Oncology. eUpdate - cervical cancer treatment recommendations. Apr 2020 [internet publication].Texto completo
223. An J, Li G, Zhang Y, et al. Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecol Oncol. 2025 Sep 18;202:33-40.Texto completo Resumo
224. Zhang J, Liu R, Wang S, et al. Bulumtatug fuvedotin (BFv, 9MW2821), a next-generation nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study. Ann Oncol. 2025 Aug;36(8):934-43. Resumo
225. ClinicalTrials.gov. A study to evaluate 9MW2821 versus treatment of physician's choice for subjects with recurrent or metastatic cervical cancer. 2024 [internet publication].Texto completo
226. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10;30(8):777-82.Texto completo Resumo
227. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018 May 1;36(13):1291-9.Texto completo Resumo
228. Wallecha A, French C, Petit R, et al. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol. 2012;2012:542851.Texto completo Resumo
229. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol. 2014;32:5(suppl);5610.
230. Huh WK, Dizon DS, Powell MA, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage I of the phase II GOG/NRG0265 study. J Clin Oncol. 2016;34:S5516.Texto completo
231. Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018 May;28(4):764-72.Texto completo Resumo
232. Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug;82(12):1333-39. Resumo
233. Wu X, Sun Y, Yang H, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet. 2024 Oct 26;404(10463):1668-76. Resumo
234. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543-50.Texto completo Resumo
235. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012 Dec 12;(12):CD007406.Texto completo Resumo
236. Zou W, Han Y, Zhang Y, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS One. 2019;14(11):e0225264.Texto completo Resumo
237. Marchetti C, Fagotti A, Tombolini V, et al. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020 Feb;83:101945. Resumo
238. Friedlander M, Grogan M; US Preventive Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002;7(4):342-7.Texto completo Resumo
239. Elit L, Fyles AW, Oliver TK, et al. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2010 Jun;17(3):65-9.Texto completo Resumo
240. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018 Sep 7;1(5):e181999.Texto completo Resumo
241. Aue-Aungkul A, Kietpeerakool C, Rattanakanokchai S, et al. Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early-stage cervical cancer. Cochrane Database Syst Rev. 2021 Jan 25;(1):CD012863.Texto completo Resumo
242. Qian M, Wang L, Xing J, et al. Prevalence of sexual dysfunction in women with cervical cancer: a systematic review and meta-analysis. Psychol Health Med. 2023 Feb;28(2):494-508. Resumo
243. Shan X, Qian M, Wang L, et al. Prevalence of pelvic floor dysfunction and sexual dysfunction in cervical cancer survivors: a systematic review and meta-analysis. Int Urogynecol J. 2023 Mar;34(3):655-64. Resumo
244. Cianci S, Tarascio M, Arcieri M, et al. Post treatment sexual function and quality of life of patients affected by cervical cancer: a systematic review. Medicina (Kaunas). 2023 Apr 4;59(4):704.Texto completo Resumo
245. Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016 Jan;118(1):160-6. Resumo
246. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer: FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95(suppl 1):S247-57. Resumo
247. Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018 Jun;127(3):423-30. Resumo
248. Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018 Jun;127(3):431-9. Resumo
249. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo
250. Naqash AR, Moey MYY, Cherie Tan XW, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022 Oct 10;40(29):3439-52.Texto completo Resumo
251. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Texto completo Resumo
252. Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017 Jul;146(1):3-10. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal